Translational Development Acquisition logo
Translational Development Acquisition
TDAC | NASDAQ
Chart Builder DCF Calculator
$10.86
-$0.02 (-0.18%)
At close: Nov 16, 2026, 4:00 PM ET
$10.90
+$0.04 (+0.37%)
After-hours: Nov 16, 2026, 4:10 PM ET

Translational Development Acquisition Company Profile

Company profile explained

Company Profile

Translational Development Acquisition Corp., founded in 2022 and headquartered in New York, New York, currently conducts no significant business operations. Its primary goal is to complete a business combination, such as a merger, amalgamation, share exchange, asset acquisition, share purchase, or reorganization, with one or more companies.

Key Executives

Name Position
Michael Hoffman Chairman of the Board & Chief Executive Officer
Avi C. Das Chief Financial Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 425 Filing
Oct 08, 2026 425 Filing
Sep 24, 2026 425 Filing
Sep 14, 2026 425 Filing
Aug 14, 2026 10-Q Quarterly Report
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 03, 2026 425 Filing
Jul 28, 2026 425 Filing
View All SEC Filings ➞
Translational Development Acquisition
Translational Development Acquisition logo
Country United States
IPO Date Feb 20, 2025
Industry Shell Companies
Sector Financial Services
Employees 2
CEO Michael Hoffman

Contact Details

52 E. 83rd Street New York City, New York 10028 United States

Stock Details

Ticker Symbol TDAC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001926599
CUSIP Number G9008W105
ISIN Number KYG9008W1050
SIC Code 6770

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.